Immunome, Inc. (NASDAQ:IMNM - Free Report) - Equities researchers at Lifesci Capital issued their Q1 2025 EPS estimates for Immunome in a research report issued on Tuesday, March 11th. Lifesci Capital analyst C. Zhu forecasts that the company will earn ($0.61) per share for the quarter. Lifesci Capital has a "Outperform" rating and a $20.00 price target on the stock. The consensus estimate for Immunome's current full-year earnings is ($2.21) per share. Lifesci Capital also issued estimates for Immunome's Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.62) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.81) EPS, Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.62) EPS and FY2026 earnings at ($2.90) EPS.
Separately, Wedbush reaffirmed an "outperform" rating and issued a $33.00 price objective on shares of Immunome in a research note on Monday, March 10th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Immunome currently has an average rating of "Buy" and an average target price of $27.17.
View Our Latest Research Report on Immunome
Immunome Trading Down 1.8 %
IMNM stock traded down $0.16 on Thursday, hitting $8.77. 453,030 shares of the company's stock traded hands, compared to its average volume of 896,133. Immunome has a 1-year low of $8.39 and a 1-year high of $26.70. The stock has a fifty day moving average of $9.98 and a 200-day moving average of $11.78. The stock has a market cap of $699.64 million, a price-to-earnings ratio of -1.08 and a beta of 1.93.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets bought a new position in shares of Immunome during the 4th quarter valued at $70,000. KLP Kapitalforvaltning AS bought a new position in shares of Immunome during the 4th quarter valued at $75,000. AlphaQuest LLC raised its holdings in shares of Immunome by 786,700.0% during the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock valued at $84,000 after purchasing an additional 7,867 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Immunome by 482.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock valued at $91,000 after purchasing an additional 7,129 shares in the last quarter. Finally, Aquatic Capital Management LLC bought a new position in shares of Immunome during the 4th quarter valued at $95,000. Institutional investors own 44.58% of the company's stock.
Insiders Place Their Bets
In other Immunome news, CEO Clay B. Siegall purchased 150,000 shares of the business's stock in a transaction dated Friday, January 31st. The shares were acquired at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the acquisition, the chief executive officer now owns 669,636 shares of the company's stock, valued at $5,189,679. This trade represents a 28.87 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 8.60% of the company's stock.
About Immunome
(
Get Free Report)
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
See Also

Before you consider Immunome, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.
While Immunome currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.